HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Shape of the Oral Glucose Tolerance Test-Glucose Response Curve in Islet Cell Antibody-Positive vs. -Negative Obese Youth Clinically Diagnosed with Type 2 Diabetes.

AbstractBACKGROUND:
The oral glucose tolerance test (OGTT)-glucose response curves (GRCs; incessant increase, monophasic, and biphasic) reflect insulin sensitivity and β-cell function, being worse in the former and superior in the latter. Here, we examined if the OGTT-GRC pattern is worse in obese antibody (glutamic acid decarboxylase 65-kDa [GAD65] and insulinoma-associated protein-2 [IA-2])-positive (Ab+) vs. -negative (Ab-) youth clinically diagnosed with type 2 diabetes (CDX-T2D).
METHODS:
Forty-seven obese youth, 15 Ab+ and 32 Ab-, were divided into three OGTT-GRC groups: incessant increase, monophasic, and biphasic. The prevalence of OGTT-GRC, clamp-measured insulin sensitivity, and β-cell function was compared.
RESULTS:
Incessant increase OGTT-GRC is the most frequent curve type and is three-fold higher in Ab+ vs. Ab- youth CDX-T2D. In Ab+ youth, there was up to 40% lower second-phase insulin secretion in the incessant increase group vs. the other two groups combined (monophasic and biphasic). In Ab- youth, while first- and second-phase insulin secretion was significantly lower in the incessant increase vs. the other two groups combined, overall β-cell function was less impaired than in Ab+ youth. In neither Ab- or Ab+ youth was OGTT-GRC related to hepatic or peripheral insulin sensitivity.
CONCLUSION:
Severe insulin deficiency, a characteristic of type 1 diabetes, seems to be related to higher prevalence of incessant increase in Ab+ vs. Ab- obese youth.
AuthorsJoon Young Kim, Hala Tfayli, Fida Bacha, Silva Arslanian
JournalJournal of obesity & metabolic syndrome (J Obes Metab Syndr) Vol. 30 Issue 2 Pg. 178-183 (Jun 30 2021) ISSN: 2508-7576 [Electronic] Korea (South)
PMID34059560 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: